AC
THRD

Aldebaran Capital’s Third Harmonic Bio THRD Stock Holding History

Aldebaran Capital’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,000
Closed -$79.8K – 41
2025
Q1 		$79.8K Buy
+23,000
New +$112K 0.08% 41

Other funds holding THRD

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Aldebaran Capital's THRD Position: Q2 2025 in Review

Aldebaran Capital sold out of Third Harmonic Bio (THRD) in Q2 2025, closing a stake of 23,000 shares — an estimated $79.8K sold.

Aldebaran Capital first reported a position in THRD in Q1 2025 and held it in 1 quarter. The position peaked at $79.8K in Q1 2025. 105 funds tracked by Wall St. Rank hold THRD as of Q2 2025.

  • Aldebaran Capital reported no remaining Third Harmonic Bio position as of Q2 2025 after selling out during the quarter.
  • Aldebaran Capital sold 23,000 Third Harmonic Bio shares in Q2 2025, an estimated $79.8K.
  • Aldebaran Capital first reported a position in Third Harmonic Bio in Q1 2025 and held it in 1 quarter.
  • Aldebaran Capital's Third Harmonic Bio position peaked at $79.8K in Q1 2025.
  • 105 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q2 2025.

Based on Aldebaran Capital's 13F filing for Q2 2025, filed 12 Aug 2025.